Tulisokibart Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Tulisokibart comprises 2 peer-reviewed publications across 2 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Colitis, Ulcerative, and Crohn Disease. Most recent publication: Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial., Lancet Gastroenterol Hepatol, 2025.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.
    Sands BE, Feagan BG, Peyrin-Biroulet L, et al. · N Engl J Med · 2024
    PubMed: PMID 39321363 · NCT04996797 (ARTEMIS-UC) · Colitis, Ulcerative
  2. Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.
    Feagan BG, Sands BE, Siegel CA, et al. · Lancet Gastroenterol Hepatol · 2025
    PubMed: PMID 40456235 · NCT05013905 (APOLLO-CD) · Crohn Disease

Publications by year

2024–2025: 2 publications.

2024
1
2025
1

Publications by indication

Colitis, Ulcerative (1)

  • Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.
    N Engl J Med · 2024 · PMID 39321363 · NCT04996797

Crohn Disease (1)

  • Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.
    Lancet Gastroenterol Hepatol · 2025 · PMID 40456235 · NCT05013905

Publications by journal

  • N Engl J Med1 paper
  • Lancet Gastroenterol Hepatol1 paper

All Tulisokibart publications (2)

2025 (1 paper)

  1. Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial.
    Feagan BG, Sands BE, Siegel CA, et al. · Lancet Gastroenterol Hepatol · 2025 · Derived
    PubMed: PMID 40456235 · NCT05013905 (APOLLO-CD) · Crohn Disease

2024 (1 paper)

  1. Phase 2 Trial of Anti-TL1A Monoclonal Antibody Tulisokibart for Ulcerative Colitis.
    Sands BE, Feagan BG, Peyrin-Biroulet L, et al. · N Engl J Med · 2024 · Trial result
    PubMed: PMID 39321363 · NCT04996797 (ARTEMIS-UC) · Colitis, Ulcerative

Sources and methodology

  • Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
  • Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
  • Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
  • Data freshness: Tue, 12 May 2026 16:53:23 GMT.
This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).